Key Facts

PIPS Key Facts
Active Substance
Active Substance:
  • Inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1) (SAR443820)
Invented Name
Not yet available
PIP Number MHRA-101030-PIP01-23
Pharmaceutical form(s)
Pharmaceutical form(s):
  • Film-coated tablet
Therapeutic area
Therapeutic area:
  • Neurology
Conditions / Indications
Conditions / Indications:
  • Treatment of Amyotrophic lateral sclerosis
Route(s) of administration
Route(s) of administration:
  • Oral use
PIP applicant
Decision Type
Decision Type
W: decision granting a waiver in all age groups for the listed condition(s).
Compliance Check
Compliance Check
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

PIPS Decision Documents
Decision Document Decision Document on a Paediatric Investigation Plan (PIP):Inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1) (SAR443820).pdf
Published Date 30/01/2024